SCHEMBL3757963

SCHEMBL3757963

FC(F)(F)c1ccccc1Cc1nc2ccc(-c3nc4sccn4c3-c3ccnc(Nc4ccccc4CN4CCCC4)n3)cc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 8/20 0.41
KDR P35968 7/20 0.41
RET P07949 5/20 0.41
STK3 Q13188 5/20 0.41
MAP4K5 Q9Y4K4 5/20 0.41
CSF1R P07333 4/20 0.41
MAP4K2 Q12851 4/20 0.41
FLT1 P17948 4/20 0.41
PTK2 Q05397 2/20 0.41
LCK P06239 6/20 0.41
MAP4K4 O95819 4/20 0.41
TAOK1 Q7L7X3 4/20 0.41
LRRK2 Q5S007 1/20 0.41
EGFR P00533 8/20 0.40
ERBB2 P04626 8/20 0.40
BRAF P15056 5/20 0.38
RAF1 P04049 3/20 0.38
FYN P06241 3/20 0.38
FGFR1 P11362 3/20 0.38
MINK1 Q8N4C8 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755296 0.82 IGF1R (0.48) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3724120 0.81 IGF1R (0.44) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3723424 0.79 IGF1R (0.52) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3720373 0.76 EGFR (0.58) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3722526 0.76 KDR (0.54) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3760282 0.74 CSF1R (0.47) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3756712 0.74 KDR (0.53) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3767040 0.74 IGF1R (0.45) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3764194 0.74 KDR (0.45) IGF1RKDRRETSTK3MAP4K5
SCHEMBL3767128 0.73 IGF1R (0.44) IGF1RKDRRETSTK3MAP4K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 EP claimed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 US claimed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 US claimed
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 EP disclosed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 US disclosed
WO-2010138575-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 IGF1R 1/4885KDR 351/4885RET 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.